readthroughSign in
Nov 10, 2026Quarterly update

Inhibikase reports Q3 2026 results, updates IMPROVE-PAH Phase 3 progress for IKT-001

The company said 79 of a planned 180 trial sites are activated across 28 countries, with an interim safety readout for Part A expected in the first half of 2027.

Inhibikase Therapeutics reported financial results for the quarter ended September 30, 2026, along with updates on its Phase 3 program for IKT-001, an oral anti-proliferative candidate for Pulmonary Arterial Hypertension, in a release dated November 10, 2026.

CEO Mark Iwicki said the company has obtained 28 country regulatory approvals in the U.S. and E.U. for the Phase 3 IMPROVE-PAH study, with 79 clinical sites activated across a range of countries.1 As of November 2026, 79 of a planned 180 clinical sites have been activated.1

The trial design includes two parts: Part A is a double blind, placebo-controlled study in approximately 140 patients with a primary endpoint of change in Pulmonary Vascular Resistance at Week 24.1 Part B begins following completion of Part A enrollment and uses an identical format except its primary endpoint is change in 6-minute walk distance at Week 24 in approximately 346 patients.1 An interim safety readout for Part A, covering 50 patients, is planned for the first half of 2027.1

In July 2026, the FDA's Office of Orphan Products Development granted Orphan Drug Designation for IKT-001.1 That same month, the company sold 25,000,000 shares of common stock to new shareholder RA Capital Management through its at-the-market facility for gross proceeds of $50 million.1

On the balance sheet, cash, cash equivalents and marketable securities totaled $193.3 million as of September 30, 2026.1 Inhibikase said this cash position, combined with existing reserves, is expected to fund operations through the topline data readout in Part B of the IMPROVE-PAH study, assuming full and timely exercise of outstanding Series A and B Warrants.1

Net loss for the quarter totaled $20.5 million, versus $11.9 million in the same quarter of 2025.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.